TY  - CONF

T1  - 1.5-Year Posttreatment Follow-Up of Radium-223 Dichloride (Ra-223) Safety in Patients (Pts) with Castration-Resistant Prostate Cancer (Crpc) and Symptomatic Bone Metastases from Alsympca: Characterization of Hematologic Safety Profiles

JO  - Annals of Oncology

PY  - 2014/09/01

AU  - Parker C

AU  - Vogelzang N

AU  - Sartor O

AU  - Bottomley D

AU  - Coleman RE

AU  - Skjorestad I

AU  - Aksnes A

AU  - Wahba M

AU  - Nilsson S

ED  - 

DO  - DOI: 10.1093/annonc/mdu336.17

PB  - Elsevier BV

VL  - 25

SP  - iv263

EP  - iv263

Y2  - 2025/10/10

ER  -